ESMO 20th World Congress on Gastrointestinal Cancer: Full Schedule

13:30 PDT

Concurrent Lunch Mini-Symposia

The Revolution in HCC: Translating to the Real World
Presented by Medscape
Room 113-115, Level 1

The Biosimilar Opportunity: Understanding Extrapolation of Indications in GI Cancer
Supported by Amgen Biosimilars
Room 116-117, Level 1

Wednesday June 20, 2018 13:30 - 14:30 PDT
Level 1

Symposia

14:45 PDT

Session I: Welcome, Selected Abstracts, and Opening Lecture

Session Chair

Mario Dicato

Chair, Luxembourg Medical Center

Josep Tabernero

Vice Chair, ESMO Representative, Vall d’Hebron University Hospital

Eric VanCutsem

Chair, University Hospital Gasthuisberg

Wednesday June 20, 2018 14:45 - 15:50 PDT
Auditorium A, Level 0

Sessions, Session I

14:46 PDT

Welcome and introduction

Faculty

Mario Dicato

Chair, Luxembourg Medical Center

Josep Tabernero

Vice Chair, ESMO Representative, Vall d’Hebron University Hospital

Eric VanCutsem

Chair, University Hospital Gasthuisberg

Wednesday June 20, 2018 14:46 - 14:50 PDT
Auditorium A, Level 0

Sessions, Session I

14:50 PDT

Presentation of selected abstracts

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors
Funda Meric-Bernstam, et al., O-001

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)
Andrew Zhu, et al., LBA-001

The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the SORAMIC trial palliative cohort
Jen Ricke, et al., O-029

Wednesday June 20, 2018 14:50 - 15:20 PDT
Auditorium A, Level 0

Sessions, Session I

15:20 PDT

Opening Lecture: The microbiome in colon cancer

Faculty

Herbert Tilg

Medical University of Innsbruck

Wednesday June 20, 2018 15:20 - 15:50 PDT
Auditorium A, Level 0

Keynote Lecture, Session I

15:50 PDT

Session II: Cancer of the Pancreas and Biliary Tract

Session Chair

Teresa Macarulla

Vall D'Hebron University Hospital

Eileen O'Reilly

Memorial Sloan Kettering Cancer Center

Wednesday June 20, 2018 15:50 - 18:30 PDT
Auditorium A, Level 0

Sessions, Session II

15:51 PDT

Genetics in pancreatic cancer: Implications for clinical practice

Faculty

Zsofia K. Stadler

Memorial Sloan Kettering Cancer Center

Wednesday June 20, 2018 15:51 - 16:10 PDT
Auditorium A, Level 0

Sessions, Session I

16:10 PDT

Are we making progress in surgery of the pancreas?

Faculty

Baki Topal

University Hospital Gasthuisberg

Wednesday June 20, 2018 16:10 - 16:30 PDT
Auditorium A, Level 0

Sessions, Session II

16:30 PDT

Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas

Faculty

Thierry Conroy

Institut de Cancérologie de Lorraine – Alexis Vautrin

Wednesday June 20, 2018 16:30 - 16:40 PDT
Auditorium A, Level 0

Sessions, Session II

16:40 PDT

Is adjuvant or neo-adjuvant treatment for resectable pancreatic cancer the way to go?

Neo-adjuvant chemotherapy: Jordan D. Berlin
Surgery plus adjuvant chemotherapy: Pascal Hammel

Faculty

Jordan D. Berlin

Vanderbilt University Medical Center

Pascal Hammel

Hôpital Beaujon

Wednesday June 20, 2018 16:40 - 17:00 PDT
Auditorium A, Level 0

Debate, Session II

17:00 PDT

Adjuvant treatment of pancreatic cancer

Monotherapy: Jean-Luc Van Laethem
Combination chemotherapy: Thierry Conroy

Faculty

Thierry Conroy

Institut de Cancérologie de Lorraine – Alexis Vautrin

Jean-Luc VanLaethem

Erasme University Hospital

Wednesday June 20, 2018 17:00 - 17:20 PDT
Auditorium A, Level 0

Debate, Session II

17:20 PDT

Presentation of selected abstracts

Geographic variation in systemic treatment of metastatic pancreatic adenocarcinoma (mPAC) patients in real world across Europe
Julien Taieb, et al., O-002

Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): a quality of life randomized cross-over study (QOLINPAC)
Gabriela Chiritescu, et al., O-003

Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (Mpdac) in the global NAPOLI-1 phase III trial
Teresa Macarulla Mercadé. et al., O-004

Wednesday June 20, 2018 17:20 - 17:50 PDT
Auditorium A, Level 0

Sessions, Session II

17:50 PDT

Improving the outcome of patients with metastatic pancreatic cancer

Faculty

Philip A. Philip

Karmanos Cancer Institute

Wednesday June 20, 2018 17:50 - 18:10 PDT
Auditorium A, Level 0

Sessions, Session II

18:10 PDT

New agents/strategies on the horizon in bile duct cancer

Faculty

Michel Ducreux

Institut Gustave Roussy

Wednesday June 20, 2018 18:10 - 18:30 PDT
Auditorium A, Level 0

Sessions, Session II

19:00 PDT

Concurrent Evening Nonprofit Symposia

ESDO European Research Workshop 2018 Hereditary GI Cancers: State of the Art in Screening and Surveillance
Presented by European Society of Digestive Oncology
Room 116, Level 1

15th ESO Colorectal Cancer Observatory: Innovations and Care in the Next 12 Months
Presented by European School of Oncology
Room 117, Level 1

Wednesday June 20, 2018 19:00 - 20:30 PDT
Level 1

Symposia

08:00 PDT

Session III: Meet the Expert Concurrent Presentations

Parallel with Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer; also Parallel with Session V: Interpreting Clinical Trials Results

Thursday June 21, 2018 08:00 - 08:50 PDT
Level 1

Concurrent Session 1, Session III

08:00 PDT

Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer

Parallel with Session III: Meet the Expert Concurrent Presentations; also Parallel with Session V: Interpreting Clinical Trials Results

Session Chair

Andrés Cervantes

INCLIVA Biomedical Research Institute, University of Valencia

Erika Martinelli

Università degli Studi della Campania L. Vanvitelli

Thursday June 21, 2018 08:00 - 09:30 PDT
Auditorium B, Level 0

Concurrent Session 2, Session IV

08:00 PDT

Session V: Interpreting Clinical Trials Results

Parallel with Session III: Meet the Expert Concurrent Presentations; also Parallel with Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer

Session Chair

Axel Grothey

Sarah Cannon Research Institute

Rachel Riechelmann

AC Camargo Cancer Center

Thursday June 21, 2018 08:00 - 09:30 PDT
Auditorium A, Level 0

Concurrent Session 3, Session V

08:01 PDT

Evaluating predictive markers and subgroups in clinical trials: Caution and best practices

Thursday June 21, 2018 08:01 - 08:20 PDT
Auditorium A, Level 0

Concurrent Session 3, Session V

08:01 PDT

Advances in surgery of rectal cancer: Workshop

Faculty

Andre D'Hoore

University Hospital Gasthuisberg

Rodrigo Perez

Instituto do Câncer do Estado de São Paulo, University of São Paulo

Thursday June 21, 2018 08:01 - 08:50 PDT
Rooms 122-123, Level 1

Concurrent Session 1, Session III

08:01 PDT

Carcinoma of unknown origin

Faculty

George Pentheroudakis

University of Ioannina

Thursday June 21, 2018 08:01 - 08:50 PDT
Rooms 131-132, Level 1

Concurrent Session 1, Session III

08:01 PDT

New endoscopic screening tools: How do they help us?

Faculty

Nadir Arber

Tel Aviv Medical Center, Tel Aviv University

Jaroslaw Regula

Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology

Thursday June 21, 2018 08:01 - 08:50 PDT
Rooms 120-121, Level 1

Concurrent Session 1, Session III

08:01 PDT

Teaching on new evolutions in radiation oncology

Session Chair

Karin Haustermans

University Hospital Gasthuisberg

Faculty

Vincenzo Valentini

Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli

Thursday June 21, 2018 08:01 - 08:50 PDT
Rooms 133-134, Level 1

Concurrent Session 1, Session III

08:01 PDT

Presentations of selected abstracts

A Multicentre, Prospective Clinical Evaluation Study For Analyzing RAS Mutational Status Utilizing Plasma Circulating Tumor DNA In Patients With Metastatic Colorectal Cancer
Yoshinori Kagawa, et al., O-005

Ultra-selection of metastatic colorectal cancer patients using Next Generation Sequencing platform to improve clinical efficacy of anti-EGFR therapy
Joana Vidal, et al., O-006

Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: final results and translational analyses of the CRICKET study by GONO
Daniele Rossini, et al., O-007

The prognostic role of microsatellite status, tumor mutational burden and protein expression in CRC
Justina Lam, et al., O-008

A Phase II multi institutional study of Nivolumab in Patients with Advanced Refractory Biliary Tract Cancers (BTC)
Richard Kim, et al., O-009

Cisplatin/5-Fluorouracil +/- Panitumumab for Patients with Non-resectable, Advanced or Metastatic Esophageal Squamous Cell Cancer: A Randomized phase III AIO/EORTC Trial with an Extensive Biomarker Program
Markus Moehler, et al., O-010

Thursday June 21, 2018 08:01 - 09:10 PDT
Auditorium B, Level 0

Concurrent Session 2, Session IV

08:20 PDT

Clinical interpretation and validity of clinical trials: When do they become practice changing?

Faculty

Alberto Sobrero

ESMO Representative, IRCCS Ospedale San Martino IST

Thursday June 21, 2018 08:20 - 08:40 PDT
Auditorium A, Level 0

Concurrent Session 3, Session V

08:40 PDT

What to use and to improve the evaluation of responses

The role of PET/CT in functional imaging: Christoph Deroose, Leuven

The role of MRI in functional imaging: Raquel Perez-Lopez, Barcelona

Faculty

Christoph Deroose

University Hospital Gasthuisberg

Raquel Perez-Lopez

Vall d'Hebron Institute of Oncology

Thursday June 21, 2018 08:40 - 09:20 PDT
Auditorium A, Level 0

Concurrent Session 3, Session V | Debate, Session V

09:10 PDT

Highlights of posters at ESMO GI on non-CRC

Faculty

Erika Martinelli

Università degli Studi della Campania L. Vanvitelli

Thursday June 21, 2018 09:10 - 09:30 PDT
Auditorium B, Level 0

Concurrent Session 2, Session IV

09:20 PDT

Panel discussion

Thursday June 21, 2018 09:20 - 09:30 PDT
Auditorium A, Level 0

Concurrent Session 3, Session V

09:30 PDT

Session VI: Esophageal and Gastric Cancers

Session Chair

Michel Ducreux

Institut Gustave Roussy

Kei Muro

Aichi Cancer Center Hospital

Thursday June 21, 2018 09:30 - 11:00 PDT
Auditorium A, Level 0

Sessions, Session VI

09:31 PDT

Management of squamous cell cancer for the esophagus

Definitive CRT: Florian Lordick
Neoadjuvant therapy followed by surgery: David H. Ilson

Faculty

David H. Ilson

Memorial Sloan Kettering Cancer Center

Florian Lordick

University Cancer Center Leipzig

Thursday June 21, 2018 09:31 - 09:55 PDT
Auditorium A, Level 0

Debate, Session VI | Sessions, Session VI

09:55 PDT

Locally advanced GE junction cancer

CRT: David H. Ilson
Peri-operative CT: David Cunningham

Faculty

David Cunningham

Royal Marsden NHS Foundation Trust

David H. Ilson

Memorial Sloan Kettering Cancer Center

Thursday June 21, 2018 09:55 - 10:20 PDT
Auditorium A, Level 0

Debate, Session VI | Sessions, Session VI

10:20 PDT

Is FLOT the only standard in the perioperative setting for gastric cancer?

Faculty

Andrés Cervantes

INCLIVA Biomedical Research Institute, University of Valencia

Thursday June 21, 2018 10:20 - 10:30 PDT
Auditorium A, Level 0

Sessions, Session VI

10:30 PDT

Keynote Lecture: Progress in unraveling the molecular taxonomy in oesophageal and gastric cancer

Faculty

Patrick Tan

Duke-NUS Medical School

Thursday June 21, 2018 10:30 - 11:00 PDT
Auditorium A, Level 0

Keynote Lecture, Session VI | Sessions, Session VI

11:00 PDT

Break and poster viewing

Posters to be presented: Non-CRC abstracts

Thursday June 21, 2018 11:00 - 11:30 PDT
Exhibition Hall

11:00 PDT

Poster discussion guided tours

Group 1 Discussant: Brigette Ma, Hong Kong
Group 2 Discussant: Thomas Seufferlein, Ulm
Group 3 Discussant: Eileen O'Reilly, New York

Faculty

Brigetta Ma

Chinese University of Hong Kong

Eileen O'Reilly

Memorial Sloan Kettering Cancer Center

Thomas Seufferlein

Ulm University

Thursday June 21, 2018 11:00 - 11:30 PDT
Exhibition Hall

11:30 PDT

Session VII: Gastric Cancer

Session Chair

Fatima Carneiro

Ipatimup and Medical Faculty

David Cunningham

Royal Marsden NHS Foundation Trust

Thursday June 21, 2018 11:30 - 13:10 PDT
Auditorium A, Level 0

Sessions, Session VII

11:31 PDT

Keynote Lecture: Hereditary aspects of gastric cancer

Faculty

Fatima Carneiro

Ipatimup and Medical Faculty

Thursday June 21, 2018 11:31 - 12:00 PDT
Auditorium A, Level 0

Keynote Lecture, Session VII | Sessions, Session VII

12:00 PDT

Presentation of selected abstracts

Overall survival results from a Phase III trial of trifluridine/tipiracil vs. placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)
Josep Tabernero, et al., LBA-002

KEYNOTE-061: phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
Kohei Shitara, et al., LBA-005

Thursday June 21, 2018 12:00 - 12:30 PDT
Auditorium A, Level 0

Sessions, Session VII

12:30 PDT

Metastatic gastric cancer: Where are we with check-point inhibitors in gastric cancer?

Faculty

Kei Muro

Aichi Cancer Center Hospital

Thursday June 21, 2018 12:30 - 12:50 PDT
Auditorium A, Level 0

Sessions, Session VII

12:50 PDT

Metastatic gastric cancer: New targeted agents in metastatic gastric cancer

Faculty

David H. Ilson

Memorial Sloan Kettering Cancer Center

Thursday June 21, 2018 12:50 - 13:10 PDT
Auditorium A, Level 0

Sessions, Session VII

13:10 PDT

Lunch

Thursday June 21, 2018 13:10 - 15:10 PDT
Level 0

13:25 PDT

Concurrent Lunch Symposia

Optimizing Holistic Patient Outcomes in Advanced Gastric/GEJ Cancer Across the Sequence of Therapy
Supported by Lilly
Rooms 111-112, Level 1

What Can We Expect from Today's and Tomorrow's Treatments in mCRC and mGC?
Supported by Servier
Rooms 113-115, Level 1

Optimizing the Continuum of Care for Patients with Pancreatic Cancer: A Case Study-Based Debate
Supported by Celgene
Rooms 116-117, Level 1

Thursday June 21, 2018 13:25 - 14:55 PDT
Level 1

Symposia

15:10 PDT

Session VIII: Diseases and Cancers of the Liver

Session Chair

Thomas Seufferlein

Ulm University

Chris Verslype

University Hospital Gasthuisberg

Thursday June 21, 2018 15:10 - 16:40 PDT
Auditorium A, Level 0

Sessions, Session VIII

15:11 PDT

Keynote Lecture: Progress in liver transplantation in GI malignancies: HCC, biliary tract, NET, colon

Faculty

René Adam

Paul Brousse Hospital

Thursday June 21, 2018 15:11 - 15:40 PDT
Auditorium A, Level 0

Keynote Lecture, Session VIII

15:40 PDT

Tumor board on HCC

Session Chair

Chris Verslype

University Hospital Gasthuisberg

Faculty

Ghassan Abou-Alfa

Memorial Sloan Kettering Cancer Center

René Adam

Paul Brousse Hospital

Jordan D. Berlin

Vanderbilt University Medical Center

Christoph Deroose

University Hospital Gasthuisberg

Thomas Seufferlein

Ulm University

Thursday June 21, 2018 15:40 - 16:10 PDT
Auditorium A, Level 0

Sessions, Session VIII

16:10 PDT

Presentation of selected abstract

Assessment of Tumor Response, AFP Response, and Time to Progression in the Phase 3 CELESTIAL Trial of Cabozantinib Versus Placebo in Advanced Hepatocellular Carcinoma (HCC)
Philippe Merle, et al., O-011

Thursday June 21, 2018 16:10 - 16:20 PDT
Auditorium A, Level 0

Sessions, Session VIII

16:20 PDT

How to integrate new agents in HCC

Faculty

Ghassan Abou-Alfa

Memorial Sloan Kettering Cancer Center

Thursday June 21, 2018 16:20 - 16:40 PDT
Auditorium A, Level 0

Sessions, Session VIII

16:40 PDT

Break and poster viewing

Posters to be presented: Clinical/basic non-CRC abstracts

Thursday June 21, 2018 16:40 - 17:10 PDT
Exhibition Hall

17:10 PDT

Session IX: Expert Highlights: What is New in This disease?

During this session, experts from a range of specialties will highlight the last 12 months of evidence-based strategies and emerging data on neuroendocrine tumors (NETs), gastrointestinal stromal tumors (GIST), anal and bile duct cancers as well as trends for 2019.

Session Chair

Nadir Arber

Tel Aviv Medical Center, Tel Aviv University

Mario Dicato

Chair, Luxembourg Medical Center

Thursday June 21, 2018 17:10 - 19:00 PDT
Auditorium A, Level 0

Sessions, Session IX

17:11 PDT

What is new in NET in the last 12 months?

Faculty

Marianne Pavel

University Hospital Erlangen

Thursday June 21, 2018 17:11 - 17:30 PDT
Auditorium A, Level 0

Sessions, Session IX

17:30 PDT

What is new in GIST in the last 12 months?

Faculty

John Zalcberg

Monash University

Thursday June 21, 2018 17:30 - 17:50 PDT
Auditorium A, Level 0

Sessions, Session IX

17:50 PDT

What is new in anal cancer in the last 12 months?

Faculty

Michel Ducreux

Institut Gustave Roussy

Thursday June 21, 2018 17:50 - 18:10 PDT
Auditorium A, Level 0

Sessions, Session IX

18:10 PDT

What is new in bile duct cancer in the last 12 months?

Faculty

Juan W. Valle

University of Manchester

Thursday June 21, 2018 18:10 - 18:30 PDT
Auditorium A, Level 0

Sessions, Session IX

18:30 PDT

Keynote Lecture: Protein Biosynthesis in Healthy Cells and in Cancer Cells

Faculty

Ada E. Yonath

Nobel Prize Laureate, Weizmann Institute of Science

Thursday June 21, 2018 18:30 - 19:00 PDT
Auditorium A, Level 0

Keynote Lecture, Session IX

19:00 PDT

20th Anniversary Celebration Reception

Thursday June 21, 2018 19:00 - 20:30 PDT
Banquet Hall, Level 2

Reception

08:00 PDT

Session XIII: Prevention and Screening of Colon Cancer

Parallel with Session X: Case Discussion on Liver Metastases; Parallel with Session XI: Presentation of Selected Abstracts: Colorectal Cancer; also Parallel with Session XII: ESMO Session: Focus on Young Medical Oncologists

Session Chair

Nadir Arber

Tel Aviv Medical Center, Tel Aviv University

Jaroslaw Regula

Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology

Friday June 22, 2018 08:00 - 09:10 PDT
Auditorium B, Level 0

Concurrent Session 4, Session XIII

08:00 PDT

Session X: Case Discussion on Liver Metastases

Parallel with Session XI: Presentation of Selected Abstracts: Colorectal Cancer; Parallel with Session XII: ESMO Session: Focus on Young Medical Oncologists; also Parallel with Session XIII: Prevention and Screening of Colon Cancer

Friday June 22, 2018 08:00 - 09:20 PDT
Rooms 120-121, Level 1

Concurrent Session 1, Session X

08:00 PDT

Session XII: ESMO Session: Focus on Young Medical Oncologists

Session Chair

Guillem Argilés

Vall D'Hebron University Hospital

Josep Tabernero

Vice Chair, ESMO Representative, Vall d’Hebron University Hospital

Friday June 22, 2018 08:00 - 09:20 PDT
Rooms 133-134, Level 1

Concurrent Session 3, Session XII

08:00 PDT

Session XI: Presentation of Selected Abstracts: Colorectal Cancer

Parallel with Session X: Case Discussion on Liver Metastases; Parallel with Session XII: ESMO Session: Focus on Young Medical Oncologists; also Parallel with Session XIII: Prevention and Screening of Colon Cancer

Session Chair

Johanna Bendell

Sarah Cannon Research Institute

Roberto Labianca

Ospedale Giovanni XXIII

Friday June 22, 2018 08:00 - 09:30 PDT
Auditorium A, Level 0

Concurrent Session 2, Session XI

08:01 PDT

Presentation of selected abstract

Plasma miRNAs signature validation for early detection of colorectal cancer
Marta Herreros-Villanueva, et al., O-044

Friday June 22, 2018 08:01 - 08:10 PDT
Auditorium B, Level 0

Concurrent Session 4, Session XIII

08:01 PDT

Role of Fusobacterium Nucleatum and intestinal microbiota in CRC pathogenesis and evolution

Faculty

Paolo G. Nuciforo

Vall d'Hebron University Hospital

Friday June 22, 2018 08:01 - 08:20 PDT
Rooms 133-134, Level 1

Concurrent Session 3, Session XII

08:01 PDT

Presentation of selected abstracts

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: Final analysis from prospective, observational CORRELATE study
Michel Ducreux, et al., O-012

Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study
Alfredo Falcone, et al., O-013

Regorafenib dose optimization study (reDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC)- An ACCRU network study
Tanios Bekaii-Saab, et al., O-014

Discussant: Roberto Labianca

Faculty

Roberto Labianca

Ospedale Giovanni XXIII

Friday June 22, 2018 08:01 - 08:40 PDT
Auditorium A, Level 0

Concurrent Session 2, Session XI

08:01 PDT

Locoregional treatment for liver metastases: How to choose within the toolbox and when to go for locoregional treatments

Session Chair

Bernard Nordlinger

Hospital Ambroise Paré

Faculty

Peter Gibbs

Walter and Eliza Hall Institute of Medical Research

Thomas Gruenberger

Kaiser-Franz-Josef Hospital

Karin Haustermans

University Hospital Gasthuisberg

Rachel Riechelmann

AC Camargo Cancer Center

Julien Taieb

Hôpital Européen Georges-Pompidou

Friday June 22, 2018 08:01 - 09:20 PDT
Rooms 120-121, Level 1

Concurrent Session 1, Session X

08:10 PDT

Genetic testing for familial and hereditary colorectal cancer

Faculty

Zsofia K. Stadler

Memorial Sloan Kettering Cancer Center

Friday June 22, 2018 08:10 - 08:30 PDT
Auditorium B, Level 0

Concurrent Session 4, Session XIII

08:20 PDT

Drugging TGF-beta pathway as a way to foster immune responses in mCRC

Faculty

Daniele Tauriello

Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology

Friday June 22, 2018 08:20 - 08:40 PDT
Rooms 133-134, Level 1

Concurrent Session 3, Session XII

08:30 PDT

Screening for colon cancer: What has been achieved in 2018 and new prospects

Faculty

Jaroslaw Regula

Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology

Friday June 22, 2018 08:30 - 08:50 PDT
Auditorium B, Level 0

Concurrent Session 4, Session XIII

08:40 PDT

The importance of having a mentor in the European oncology environment

Faculty

Andrés Cervantes

INCLIVA Biomedical Research Institute, University of Valencia

Friday June 22, 2018 08:40 - 09:00 PDT
Rooms 133-134, Level 1

Concurrent Session 3, Session XII

08:40 PDT

Presentation of selected abstracts

A two-arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results
Gabriela Chiritescu, et al., O-015

First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study
Filippo Pietrantonio, et al., O-016

FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: final results of the phase II randomized MOMA trial by GONO
Federica Marmorino, et al., O-017

Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab plus cobimetinib and atezolizumab monotherapy vs. regorafenib in chemotherapy-refractory
Johanna Bendell, et al., LBA-004

Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208
Howard Hochster, et al., O-030

Friday June 22, 2018 08:40 - 09:30 PDT
Auditorium A, Level 0

Concurrent Session 2, Session XI

08:50 PDT

Will chemoprevention become a reality?

Faculty

Nadir Arber

Tel Aviv Medical Center, Tel Aviv University

Friday June 22, 2018 08:50 - 09:10 PDT
Auditorium B, Level 0

Concurrent Session 4, Session XIII

09:00 PDT

How to find a good mentor in Europe

Faculty

Erika Martinelli

Università degli Studi della Campania L. Vanvitelli

Friday June 22, 2018 09:00 - 09:20 PDT
Rooms 133-134, Level 1

Concurrent Session 3, Session XII

09:30 PDT

Session XIV: Highlights

Session Chair

Mario Dicato

Chair, Luxembourg Medical Center

Eric VanCutsem

Chair, University Hospital Gasthuisberg

Friday June 22, 2018 09:30 - 10:35 PDT
Auditorium A, Level 0

Sessions, Session XIV

09:31 PDT

Keynote Lecture: Understanding relevant immune mechanisms in GI oncology

Faculty

Pierre Coulie

Université catholique de Louvain, Institut de Duve

Friday June 22, 2018 09:31 - 10:00 PDT
Auditorium A, Level 0

Keynote Lecture, Session XIV

10:00 PDT

Keynote Lecture: Coping with escalating healthcare costs in 2018 and beyond

Faculty

Josep Tabernero

Vice Chair, ESMO Representative, Vall d’Hebron University Hospital

Friday June 22, 2018 10:00 - 10:30 PDT
Auditorium A, Level 0

Keynote Lecture, Session XIV

10:30 PDT

Travel Grant Award Ceremony

Friday June 22, 2018 10:30 - 10:35 PDT
Auditorium A, Level 0

Sessions, Session XIV

10:35 PDT

Break and poster viewing

Abstracts to be presented: Clinical/basic CRC abstracts

Friday June 22, 2018 10:35 - 11:05 PDT
Exhibition Hall

10:35 PDT

Poster discussion guided tours

Group 1 Discussant: Bernard Nordlinger
Group 2 Discussant: Thomas Seufferlein
Group 3 Discussant: Gerald Prager

Faculty

Bernard Nordlinger

Hospital Ambroise Paré

Gerald Prager

Medical Unviersity of Vienna

Thomas Seufferlein

Ulm University

Friday June 22, 2018 10:35 - 11:05 PDT
Exhibition Hall

11:05 PDT

Session XV: Multimodality Therapy for Rectal Cancer

Session Chair

Regina G.H. Beets-Tan

The Netherlands Cancer Institute

Karin Haustermans

University Hospital Gasthuisberg

Friday June 22, 2018 11:05 - 12:45 PDT
Auditorium A, Level 0

Sessions, Session XV

11:06 PDT

Keynote Lecture: TME surgery as seen by the creator

Faculty

R.J. (Bill) Heald

Pelican Cancer Foundation

Friday June 22, 2018 11:06 - 11:35 PDT
Auditorium A, Level 0

Keynote Lecture, Session XV

11:35 PDT

Debate: This house believes multiparametric MRI is the holy grail for organ preservation in rectal cancer

For the motion: Regina Beets-Tan
Against the motion: Karin Haustermans

Faculty

Regina G.H. Beets-Tan

The Netherlands Cancer Institute

Karin Haustermans

University Hospital Gasthuisberg

Friday June 22, 2018 11:35 - 11:55 PDT
Auditorium A, Level 0

Debate, Session XV

11:55 PDT

Rectal cancer after neoadjuvant therapy with complete clinical response

Surgery: Eric Rullier
Watchful waiting: Rodrigo Perez

Faculty

Rodrigo Perez

Instituto do Câncer do Estado de São Paulo, University of São Paulo

Eric Rullier

Haut-Lévêque Hospital

Friday June 22, 2018 11:55 - 12:15 PDT
Auditorium A, Level 0

Debate, Session XV

12:15 PDT

Evolution and innovations in rectal cancer surgery

Faculty

Andre D'Hoore

University Hospital Gasthuisberg

Friday June 22, 2018 12:15 - 12:35 PDT
Auditorium A, Level 0

Sessions, Session XV

12:35 PDT

Presentation of selected abstract

PETACC-6: Preop chemoradiation and postop chemotherapy (capecitabin +/- oxaliplatin) in locally advanced rectal cancer: Overall survival after long term follow-up
Hans-Joachim Schmoll, et al., O-019

Friday June 22, 2018 12:35 - 12:45 PDT
Auditorium A, Level 0

Sessions, Session XV

12:45 PDT

Lunch

Friday June 22, 2018 12:45 - 14:45 PDT
Level 0

13:00 PDT

Concurrent Lunch Symposia

New Treatment Paradigms in GI Cancers: Targeted and Immunotherapy Combinations in mCRC and Advanced HCC
Supported by Roche
Rooms 111-112, Level 1

Bridging Data to Clinical Practice for Patients with Metastatic Colorectal Cancer: An Interactive Peer-to-Peer Discussion
Supported by Sanofi Genzyme
Rooms 113-115, Level 1

Advancing Clinical Practice and Patient Care in RAS Wild-Type mCRC
Supported by Amgen
Rooms 116-117, Level 1

Friday June 22, 2018 13:00 - 14:30 PDT
Level 1

Symposia

14:45 PDT

Session XVI: Molecular Biology in CRC

Session Chair

Fortunato Ciardiello

ESMO Representative, Second University of Naples

Brigetta Ma

Chinese University of Hong Kong

Friday June 22, 2018 14:45 - 16:45 PDT
Auditorium A, Level 0

Sessions, Session XVI

14:46 PDT

How to approach the patient with a BRAF mutant tumor

Faculty

Chloe Atreya

UCSF Helen Diller Family Comprehensive Cancer Center

Friday June 22, 2018 14:46 - 15:05 PDT
Auditorium A, Level 0

Sessions, Session XVI

15:05 PDT

Current status and perspectives on liquid biopsies in GI cancer

Faculty

Fortunato Ciardiello

ESMO Representative, Second University of Naples

Friday June 22, 2018 15:05 - 15:25 PDT
Auditorium A, Level 0

Sessions, Session XVI

15:25 PDT

Is circulating DNA relevant in stage II colon cancer?

Faculty

Peter Gibbs

Walter and Eliza Hall Institute of Medical Research

Friday June 22, 2018 15:25 - 15:45 PDT
Auditorium A, Level 0

Sessions, Session XVI

15:45 PDT

New insights on the molecular and immunologic classifications in CRC 8

Faculty

Sabine Tejpar

University Hospital Gasthuisberg

Friday June 22, 2018 15:45 - 16:05 PDT
Auditorium A, Level 0

Sessions, Session XVI

16:05 PDT

Is broad NGS testing useful in patients with metastatic colorectal cancer?

Pro: Rodrigo Dienstmann
Con: Howard Hochster

Faculty

Rodrigo Dienstmann

Vall d'Hebron Institute of Oncology

Howard Hochster

Rutgers Cancer Institute of New Jersey

Friday June 22, 2018 16:05 - 16:35 PDT
Auditorium A, Level 0

Debate, Session XVI

16:35 PDT

Presentation of selected abstract

Activity of larotrectinib in patients with TRK fusion GI malignancies
Michael Nathenson, et al., O-020

Friday June 22, 2018 16:35 - 16:45 PDT
Auditorium A, Level 0

Sessions, Session XVI

16:45 PDT

Break and poster viewing

Posters to be presented: Clinical/basic CRC abstracts

Friday June 22, 2018 16:45 - 17:15 PDT
Exhibition Hall

17:15 PDT

Session XVII: Immune Mechanisms and Immune Therapy in GI Cancer

This session will highlight the mechanisms of action, pathways, and rationale for using immunotherapy to treat GI malignancies, assess guideline recommendations for biomarker testing to guide treatment selection across tumor types, evaluate the clinical profiles of current and emerging therapies designed to inhibit the deleterious effects of these diseases, evaluate safety and efficacy data reported to date, and assess potential clinical applications.

Session Chair

Ali Shamseddine

American University of Beirut Medical Center

Alberto Sobrero

ESMO Representative, IRCCS Ospedale San Martino IST

Friday June 22, 2018 17:15 - 18:20 PDT
Auditorium A, Level 0

Sessions, Session XVII

17:16 PDT

Presentation of selected abstract

Safety and Antitumor Activity of Pembrolizumab in Patients with Advanced Microsatellite Instability–High (MSI-H) Colorectal Cancer: KEYNOTE-164
Dung Le, et al., O-021

Friday June 22, 2018 17:16 - 17:25 PDT
Auditorium A, Level 0

Sessions, Session XVII

17:25 PDT

Highlights of Posters at ESMO GI on colorectal cancer

Faculty

Takayuki Yoshino

National Cancer Center Hospital East

Friday June 22, 2018 17:25 - 17:40 PDT
Auditorium A, Level 0

Sessions, Session XVII

17:40 PDT

How to increase immunogenicity in MSS CRC

Faculty

Guillem Argilés

Vall D'Hebron University Hospital

Friday June 22, 2018 17:40 - 18:00 PDT
Auditorium A, Level 0

Sessions, Session XVII

18:00 PDT

Are we making progress with Immuno-Oncologic in pancreatic cancer?

Faculty

Eileen O'Reilly

Memorial Sloan Kettering Cancer Center

Friday June 22, 2018 18:00 - 18:20 PDT
Auditorium A, Level 0

Sessions, Session XVII

18:20 PDT

Session XVIII: Impact of New Evolutions in GI Oncology in Emerging Regions

Friday June 22, 2018 18:20 - 19:10 PDT
Auditorium A, Level 0

Sessions, Session XVIII

18:21 PDT

What do the new evolutions in GI cancer mean for my practice?

South America: Jorge Gallardo
Middle East: Ali Shamsheddine
Asia: Brigette Ma

Faculty

Jorge Gallardo

Chilean Foundation for Oncology Development

Brigetta Ma

Chinese University of Hong Kong

Ali Shamseddine

American University of Beirut Medical Center

Friday June 22, 2018 18:21 - 19:10 PDT
Auditorium A, Level 0

Debate, Session XVIII

08:30 PDT

Session XIX: Colorectal Cancer: How to Deal with New Treatments

Session Chair

Alberto Sobrero

ESMO Representative, IRCCS Ospedale San Martino IST

Josep Tabernero

Vice Chair, ESMO Representative, Vall d’Hebron University Hospital

Saturday June 23, 2018 08:30 - 09:30 PDT
Auditorium A, Level 0

Sessions, Session XIX

08:31 PDT

How can we deal with the explosion of new treatments

FDA: Steven Lemery
EMA: Jorge Camarero
ESMO: Jean-Yves Douillard

Faculty

Jorge Camarero

CHMP, European Medicines Agency/Spanish Medicines Agency

Jean-Yves Douillard

European Society for Medical Oncology

Steven Lemery

United States Food & Drug Administration

Saturday June 23, 2018 08:31 - 09:30 PDT
Auditorium A, Level 0

Debate, Session XIX

09:30 PDT

Session XX: Colorectal Cancer

Session Chair

Josep Tabernero

Vice Chair, ESMO Representative, Vall d’Hebron University Hospital

Eric VanCutsem

Chair, University Hospital Gasthuisberg

Saturday June 23, 2018 09:30 - 10:40 PDT
Auditorium A, Level 0

Sessions, Session XX

09:31 PDT

Presentation of selected abstracts

Phase II study evaluating trifluridine/tipiracil+bevacizumab and capecitabine+bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis
Eric Van Cutsem, et al., O-022

FOLFOX/Bevacizumab +/- Irinotecan in advanced colorectal cancer (CHARTA): long term outcome
Hans-Joachim Schmoll, et al., O-023

mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109)
Michael Geissler, et al., O-024

Selecting the optimal first-line treatment in advanced colorectal cancer:
Discussion of abstracts O-022 to O-024
David Cunningham

Faculty

David Cunningham

Royal Marsden NHS Foundation Trust

Saturday June 23, 2018 09:31 - 10:10 PDT
Auditorium A, Level 0

Sessions, Session XX

10:10 PDT

Explaining the unexplainable: CALGB vs FIRE-3 discrepant data

Faculty

Dan Aderka

Sheba Medical Center

Saturday June 23, 2018 10:10 - 10:25 PDT
Auditorium A, Level 0

Sessions, Session XX

10:25 PDT

The left versus right colon cancer story: What is the truth?

Faculty

Volker Heinemann

University of Munich

Saturday June 23, 2018 10:25 - 10:40 PDT
Auditorium A, Level 0

Sessions, Session XX

10:40 PDT

Break

Saturday June 23, 2018 10:40 - 11:10 PDT
Level 0

Sessions, Session XX

11:10 PDT

Session XX: Colorectal Cancer (Continued)

Session Chair

Josep Tabernero

Vice Chair, ESMO Representative, Vall d’Hebron University Hospital

Eric VanCutsem

Chair, University Hospital Gasthuisberg

Saturday June 23, 2018 11:10 - 13:10 PDT
Auditorium A, Level 0

Sessions, Session XX

11:11 PDT

How to improve on the outcome in RAS mutant tumors

Faculty

Heinz-Josef Lenz

USC Norris Comprehensive Cancer Center

Saturday June 23, 2018 11:11 - 11:30 PDT
Auditorium A, Level 0

Sessions, Session XX

11:30 PDT

Presentation of selected abstracts

Association between tumor mutation burden (TMB) and MLH1, PMS2, MSH2, and MSH6 alterations in 395 microsatellite instability-high (MSI-High) gastrointestinal (GI) tumors
Mohamed Salem, et al., O-025

Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy
Julian Hamfjord, et al., O-026

BEACON CRC Study Safety Lead-in: Assessment of the BRAF Inhibitor Encorafenib + MEK Inhibitor Binimetinib + Anti–Epidermal Growth Factor Receptor Antibody Cetuximab for BRAFV600E Metastatic Colorectal Cancer
Eric Van Cutsem, et al., O-027

Discussant: Ramon Salazar

Faculty

Ramon Salazar

Catalan Institute Of Oncology

Saturday June 23, 2018 11:30 - 12:10 PDT
Auditorium A, Level 0

Sessions, Session XX

12:10 PDT

Can we refine the selection for adjuvant treatment in stage II colon cancer?

Faculty

Axel Grothey

Sarah Cannon Research Institute

Saturday June 23, 2018 12:10 - 12:30 PDT
Auditorium A, Level 0

Sessions, Session XX

12:30 PDT

Presentation of selected abstract

Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaboration
Shintaro Takeuchi, et al., O-028

Saturday June 23, 2018 12:30 - 12:40 PDT
Auditorium A, Level 0

Sessions, Session XX

12:40 PDT

Can we refine the selection for adjuvant treatment in stage III colon cancer?

Faculty

Thierry André

Hôpital Saint-Antoine

Saturday June 23, 2018 12:40 - 13:10 PDT
Auditorium A, Level 0

Sessions, Session XX

13:10 PDT

Lunch

Saturday June 23, 2018 13:10 - 15:10 PDT
Level 0

13:25 PDT

Concurrent Lunch Symposia

Contemporary Management of Metastatic Pancreatic Cancer: Exploring the Nuances of Patient Care Across the Disease Continuum
Presented by prIME Oncology
Rooms 113-115, Level 1

Optimizing Sequencing of Regorafenib in the Treatment of CRC, HCC, GIST, and Other Solid Tumors
Supported by Bayer
Rooms 116-117, Level 1

Saturday June 23, 2018 13:25 - 14:55 PDT
Level 1

Symposia

15:10 PDT

Session XXI: From 1999 to 2018 and Beyond

Session Chair

Mario Dicato

Chair, Luxembourg Medical Center

Bernard Nordlinger

Hospital Ambroise Paré

Saturday June 23, 2018 15:10 - 16:40 PDT
Auditorium A, Level 0

Sessions, Session XXI

15:11 PDT

Celebration Lecture: The history of GI cancer: What has been achieved over the last 20 years?

As the standard of care and novel strategies for the management of GI malignancies continue to evolve, this session will highlight the most impactful research advances and clinical discoveries that have been instrumental in reducing mortality and morbidity associated with these diseases over the past 20 years.

Faculty